A commonly known steroid drug has been found to greatly improve survival for COVID-19 patients. In fact, among severe patients, the steroid, Dexamethasone, reduced the number of deaths by one-third in a study conducted by the University of Oxford.
Two major journals in the healthcare space are reviewing what happened and how to move forward with data requirements after a controversial study on the impact of hydroxychloroquine led to a retraction and backlash.
Centene, one of the nation’s largest insurance and managed care companies, has teamed up with the National Minority Quality Forum (NMQF) to launch a research partnership that will dive into the impacts of COVID-19 on minorities.
A group consisting of 140 scientists and physicians has spoken out against a study published in The Lancet that found an association between the use of the drug hydroxychloroquine and a higher death rate among COVID-19 patients.